LONDON–(COMMERCIAL THREAD) – Despite global disruption to family planning services due to the Covid-19 pandemic, WomanCare Global Trading CIC (DKT WomanCare) and Shanghai Dahua Pharmaceutical Co., Ltd. (Dahua) are proud to announce a price reduction for Levoplant, a contraceptive stick implant prequalified by the World Health Organization (WHO) for use up to three years. Levoplant is currently registered and is increasing women’s reproductive health empowerment in over 30 countries around the world.
Levoplant will now be fair $ 6.70 USD (FOB) for qualified buyers in FP2020 target countries, a decrease of $ 0.20 from the current access price of US $ 6.90 – and the second such reduction in the past three years. Despite Covid-19 and a general climate of significant cost increases in the pharmaceutical industry, especially for raw materials like levonorgestrel (the active pharmaceutical ingredient in Levoplant), this price reduction will help expand access to a quality contraceptive for those who need it most.
“Although the cost of levonorgestrel has doubled since 2018, we are mitigating the impact through more efficient production processes, increased automation and innovative agreements with our component suppliers,” said Bin Song, Managing Director of Dahua. “Our partnership with DKT has been instrumental in growing the Levoplant market globally, resulting in greater economies of scale. We are happy to avoid the price increases and even pass some of these savings on to our customers. ”
As Levoplant sales have tripled since DKT WomanCare took over marketing and distribution in 2018, the United Nations Population Fund predicts Covid-related lockdowns could lose 47 million women globally essential access to contraception.
“The Covid-19 pandemic has put enormous pressure on health systems and health budgets around the world,” says Chris Purdy, president and CEO of DKT International, one of the largest family planning organizations in the world. world and the parent company of DKT WomanCare. “Family planning programs have been downgraded and this burden falls disproportionately on women and girls in poor countries. The uncertainty surrounding the pandemic is leading many couples to delay the birth of their next child. In this context, reducing the cost of Levoplant by 20 cents is an important contribution to help them acquire a certain stability in their life.
As major donors cut back on budget commitments, lowering Levoplant prices is a positive for the global family planning community. The British government’s Foreign, Commonwealth & Development Office (FCDO) announced in April cuts of about £ 130 million ($ 184 million) to the United Nations Population Fund.
“Every dollar in family planning needs to go further,” Purdy adds. “Implants continue to be one of the most popular contraceptive methods in Africa, so this price reduction will allow women and other stakeholders with tight finances to continue to afford a high-quality implant option.” . ”
“We are 16% more affordable than three years ago and 20% more affordable than the other implant options available today”, says Jacques-Antoine Martin, Managing Director of DKT WomanCare. “DKT and Dahua are Recognized award leaders in the category as we focus on expanding into new markets and training healthcare providers. Our goal is to shape the market by delivering world-class implants at the best price, especially in developing countries.
While donor funding provides essential support to resource-limited countries, most (> 80%) of global expenditure on contraceptive supplies is borne by individuals according to RHSC’s 2019 commodity gap analysis.
“DKT WomanCare creates structural and long-term solutions to systemic challenges, such as product financing and donor dependence, by engaging in innovative partnerships and distribution models to put downward pressure on prices. Purdy concludes. “We want to provide our customers with a fantastic product and show them that $ 6.70 is a fair and affordable price to pay for three years of worry-free sex.”
In 2020, DKT WomanCare sold over 2.2 million sets of Levoplant, which helped prevent around 1.86 million unwanted pregnancies.
DKT WomanCare Global is a globally integrated sexual and reproductive health company that helps women live their lives to the fullest. We are making premium contraceptives and safe abortion products more available, accessible and affordable in more than 90 countries around the world. Learn more at www.dktwomancare.org.
Created in 1991, Shanghai Dahua Pharmaceutical Co., Ltd. is a trusted global leader in the production of safe and effective long-acting contraceptive implants. Dahua is committed to ensuring the quality, safety and efficacy of its products for the benefit of end users around the world.